<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01777451</url>
  </required_header>
  <id_info>
    <org_study_id>NEFIMAR</org_study_id>
    <secondary_id>S52684</secondary_id>
    <nct_id>NCT01777451</nct_id>
  </id_info>
  <brief_title>Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis</brief_title>
  <acronym>NEFIMAR</acronym>
  <official_title>Whole Body Magnetic Resonance Imaging With Diffusion Weighted Imaging : Potential Role in Neurofibromatosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Whole body MRI will be performed in patients with neurofibromatosis Type 1

      PURPOSE 1:

      To determine the total tumor load (neurofibroma) and to diagnose plexiform neurofibromas or
      malignant peripheral nerve sheath tumors. All patients will be scanned two years after the
      baseline whole body MRI to investigate to investigate the changes of total tumor load.

      PURPOSE 2: added value of diffusion weighted imaging in diagnosis of high-risk neurofibromas

      PURPOSE 3 : to determine the apparent diffusion coefficient of the malignant nerve sheath
      tumors and neurofibroma.

      PURPOSE 4 : correlation between histopathology of the surgically resected
      neurofibroma/malignant nerve sheath tumors and MRI findings
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2010</start_date>
  <completion_date type="Anticipated">January 2014</completion_date>
  <primary_completion_date type="Anticipated">January 2013</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Estimation of total tumor load and diagnosis of high-risk neurofibromas</measure>
    <time_frame>1 month</time_frame>
    <description>Estimation of the total tumor load of neurofibromas with whole body MRI (head to knee). Diagnosis of high risk neurofibroma in the chest, abdomen, pelvis, and extremities with T2-weighted sequence and diffusion weighted sequence.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To diagnose high-risk neurofibroma</measure>
    <time_frame>2 months</time_frame>
    <description>Some patients with neurofibromatosis have lesions, pre-malignant or malignant neurofibromas. Additional imaging (PET-CT), a biopsy or surgical treatment is necessary in combination with histopathology of the lesion.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Whole Body Imaging</condition>
  <condition>Magnetic Resonance Imaging</condition>
  <condition>Neurofibromatosis 1</condition>
  <condition>Diffusion Magnetic Resonance Imaging</condition>
  <condition>Peripheral Nerve Sheath Tumors, Malignant</condition>
  <arm_group>
    <arm_group_label>Neurofibromatosis 1</arm_group_label>
    <description>All patients diagnosed with neurofibromatosis type 1. GROUP 1:ADDITIONAL IMAGING OR SURGERY There will be patients with high-risk neurofibromas (potential malignant). These patients will underwent additional examinations or surgery (outside this study). Follow-up MRI within 2 years (study MRI )
GROUP 2:
No suspicious lesions at MRI. Follow-up within 2 years(Study MRI).</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Additional imaging or surgery</intervention_name>
    <description>No specific intervention is necessary. If a suspicious lesion is diagnosed on MRI, further investigation will be planned (PET-CT or surgery - biopsy)</description>
    <arm_group_label>Neurofibromatosis 1</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All patients with a clinically proven neurofibromatosis type 1 can be included.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with neurofibromatosis type 1, between 6 and 50 years old

        Exclusion Criteria:

          -  Patients who are not allowed to be scanned on MRI (contra-indications: pacemaker ed.)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Pans, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universitaire Ziekenhuizen Leuven</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Steven Pans, MD</last_name>
    <phone>3216340505s</phone>
    <email>steven.pans@uzleuven.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Steven Pans, MD</last_name>
      <phone>3216340505</phone>
      <email>steven.pans@uzleuven.be</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Tucker T, Friedman JM, Friedrich RE, Wenzel R, FÃ¼nsterer C, Mautner VF. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas. J Med Genet. 2009 Feb;46(2):81-5. doi: 10.1136/jmg.2008.061051. Epub 2008 Oct 17.</citation>
    <PMID>18930997</PMID>
  </reference>
  <reference>
    <citation>Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, Plotkin SR. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology. 2009 Mar;250(3):665-73. doi: 10.1148/radiol.2503080700.</citation>
    <PMID>19244040</PMID>
  </reference>
  <reference>
    <citation>Van Meerbeeck SF, Verstraete KL, Janssens S, Mortier G. Whole body MR imaging in neurofibromatosis type 1. Eur J Radiol. 2009 Feb;69(2):236-42. doi: 10.1016/j.ejrad.2008.10.024. Epub 2008 Dec 16.</citation>
    <PMID>19091504</PMID>
  </reference>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 23, 2013</study_first_submitted>
  <study_first_submitted_qc>January 23, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 28, 2013</study_first_posted>
  <last_update_submitted>January 23, 2013</last_update_submitted>
  <last_update_submitted_qc>January 23, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Steven Pans</investigator_full_name>
    <investigator_title>Medical Doctor Radiologist</investigator_title>
  </responsible_party>
  <keyword>Whole Body Imaging</keyword>
  <keyword>Magnetic Resonance Imaging</keyword>
  <keyword>Neurofibromatosis 1</keyword>
  <keyword>Diffusion Magnetic Resonance Imaging</keyword>
  <keyword>Peripheral Nerve Sheath Tumors, Malignant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neurofibromatoses</mesh_term>
    <mesh_term>Neurofibromatosis 1</mesh_term>
    <mesh_term>Neurofibroma</mesh_term>
    <mesh_term>Nerve Sheath Neoplasms</mesh_term>
    <mesh_term>Neurilemmoma</mesh_term>
    <mesh_term>Neurofibrosarcoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

